EUVIMEDEUVIMED entdecken
EditorialKommentar

Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?

Arnab Basu iD, Soroush Rais-Bahrami iD

JNCI: Journal of the National Cancer Institute · 2024

DOI: 10.1093/jnci/djae025 ↗

Kurz gefasst

Editorial in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Arnab Basu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Multifactorial Inheritance, Genetic Predisposition to Disease. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is substantial heterogeneity in the biology and clinical course of prostate cancer across patients with this diagnosis. Although prostate cancer is the most common cancer and second-leading cause of cancer-related mortality in American men, unlike lung, breast, or colon cancer, there are no consistent guidelines that support universal screening because of the risk of false positives and the potential for overtreatment. Thus, there is great interest in evaluating reliable biomarkers of elevated prostate cancer risk. Polygenic risk scores (PRSs) are a potential tools to improve clinical outcomes by identifying patients who may benefit from more intensive monitoring or therapy. Ancestry plays an important role in prostate cancer biology, with African American patients having a 64% greater risk of developing prostate cancer than their European counterparts (1). Further, African American patients experience worse outcomes, with an earlier age of presentation and higher rates of metastatic disease (2). Unfortunately, many risk stratification tools have been developed on European ancestry cohorts that may not be optimal for evaluating prostate cancer risk in other ancestral groups (3). In this issue of the Journal, Lee and colleagues (4) examine a polygenic hazard score (PHS)—specifically, PHS290—in a large cohort of 36 717 veterans, among whom 10 297 (28.04%) are of African American ancestry. Their investigation focuses retrospectively on patients undergoing their first prostate biopsy, and they correlate the germline risk of prostate cancer based on the polygenic hazard score with subsequent positive biopsy findings. The results suggest that although the PHS290 is associated with a higher risk of positive biopsy results, it performs better in patients of European ancestry (odds ratio [OR] = 3.89, 95% confidence interval [CI] = 3.62 to 4.18) than in those of African ancestry (OR = 2.18, 95% CI = 1.93 to 2.47). PHS290 also appears to be associated with an elevated risk of diagnosing more aggressive prostate cancer, although it is not specific for it. These findings are congruent with other studies. In a study by Kim et al. (5), 3 distinct polygenic risk scores were validated in a sub-Saharan cohort. These tools included the PRS269, which is a unique score that uses ancestry-specific weights; another 147-marker polygenic risk score developed on a European population; and finally the PHS46+, which is a modified polygenic hazard score containing 3 loci specifically for men of African ancestry. Despite these strategies, the polygenic predictions of case vs control status showed a pattern of decreased performance for individuals of African descent (area under the curve = 0.502-0.585, OR = 0.95-2.01) compared with performance among those of European descent (area under the curve = 0.608-0.707, OR = 2.37-5.71), consistent with what Lee and colleagues report (4). Furthermore, even among patients of African origin, the models predicted more effectively for those of western African ancestry than for those of southern African ancestry, highlighting the challenges in our current understanding the genomic heterogeneity of populations that originate from such a large and diverse continent. Most African American patients can trace their ancestry to western Africa, with much smaller numbers from the eastern and southern regions of the continent (6). In a group of patients undergoing prostate biopsy, we showed that men with western African ancestry have a higher risk of a positive prostate biopsy result and more aggressive prostate cancer. In this study, we noted that almost 80% of self-identified African American men in our cohort had West African ancestry based on ancestry genotyping (7). As a result of these shortcomings, research is currently underway to expand the relevance of these scores by mining large, inclusive datasets. Recently, Chen et al. published the largest such meta-analysis, combining 10 genome wide association studies containing 19 378 patients and 61 620 controls of African ancestry with prostate cancer. As a result, 9 novel risk variants were discovered, with 7 unique to patients of African ancestry. When added to PRS269, the newly derived score—PRS278 (278 = 269 + 9)—appeared to perform much better, with a strong association for aggressive variant prostate cancers in patients with African ancestry, a 3-fold higher risk for men in the top 10% (OR = 3.19, 95% CI = 3.00 to 3.40), and more than 5-fold higher risk for men in the top 1% (OR = 5.75, 95% CI = 5.06 to 6.53) compared with men at average genetic risk (8). Today, these new studies are providing critical data necessary to update our risk evaluation tools in an intentionally inclusive way and advance the quality of care for all patients with prostate cancer. Although the work from Lee and colleagues (4) in this issue focuses on germline risk scores for prostate cancer diagnosis, closer investigation of genomic data holds the promise of improving outcomes for patients of African ancestry at all stages of their disease course, including cases of advanced, even metastatic prostate cancer. An example of this is with the discovery of homologous recombination repair defects in prostate cancers. Prostate tumors that have these defects can now be effectively targeted with orally bioavailable therapies called poly-ADP ribose polymerase inhibitors, which include drugs such as olaparib, niraparib, and talazoparib. Candidacy for therapy depends on the detection of a pathologic alteration in these homologous recombination repair genes. Patients with variants of uncertain significance are not candidates for these targeted therapies. It is important to note that mutation frequencies for homologous recombination repair defects, particularly those involving variants of uncertain significance, exhibit notable disparities across racial backgrounds. Patients with African ancestry exhibit almost a 4-times higher prevalence of BRCA1/2 variants of uncertain significance compared with their White counterparts (4.6% vs 1.6%, respectively) (9). These disparities are not restricted to African Americans: The incidence of variants of uncertain significance among Hispanic men surpasses that of non-Hispanic White men, as evidenced in retrospective analyses of 2 distinct cohorts of patients with prostate cancer (21.5% vs 16.6% and 20.6% vs 7.2%, respectively) (10). These findings reflect the inadequate data available on these patients and underscores the importance for improving the generalizability of these risk stratification tools. Promoting guideline-driven germline testing for men at a recognizably elevated risk of harboring hereditary predispositions to prostate cancer will help ameliorate health-care disparities among minority populations, ultimately enhancing screening practices and early detection for the relatives of affected individuals. Finally, the development of prognostic models for high-risk patients based on gene profiling has emerged as a focal point of research inquiry. These tests enable us to properly allocate more involved, multiarm treatment to the right patients, thus sparing toxicity to those at lower risk of adverse outcomes from their disease biology. Unfortunately, most currently approved clinical genomic classifiers also suffer from the relative lack of patients with African ancestry in their underlying development cohorts. We believe that the continued exploration of race-inclusive biomarkers, as done by Lee and colleagues (4), will yield a more precise risk stratification toolbox across disease stages and subtypes, surpassing the accuracy of currently available classifiers for all our patients. No new data were generated or analyzed for this editorial. Arnab Basu, MD, MPH (Writing—original draft; Writing—review & editing), Soroush Rais-Bahrami, MD, MBA (Conceptualization; Supervision; Writing—original draft; Writing—review & editing) No funding was use for this editorial. Arnab Basu receives research funding from Natera Inc, Merck & Co, Pfizer Inc, and Bristol-Myers Squibb Company. He has received honoraria from Eisai Co, Ltd; Natera Inc; Health & Wellness Partners, LLC; and AVEO Pharmaceuticals. He has served as a consultant to Eisai Co, Ltd; Seagen (formerly Seattle Genetics); EMD Serono Inc; and AVEO Pharmaceuticals. Soroush Rais-Bahrami receives research funding from the National Institutes of Health and National Cancer Institute; the US Department of Defense; Blue Earth Diagnostics Ltd; Genomic Health, Inc/Exact Sciences; Astellas Pharma Inc; and Progenics Pharmaceuticals, Inc/Lantheus. He serves as a consultant to Philips Corp; Blue Earth Diagnostics Ltd; Genomic Health, Inc; Bayer Healthcare Pharmaceuticals LLC; Intuitive Surgical; Sanofi/Genzyme; Progenics Pharmaceuticals, Inc/Lantheus; GE HealthCare; and Boston Scientific. None.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMultifactorial InheritanceGenetic Predisposition to DiseaseHumansMaleGenomicsGenome-Wide Association StudyRisk FactorsRisk Assessment

Autor:innen und Institutionen

  • Department of Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
  • O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
  • Department of Urology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
  • Department of Radiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

ORCID-Profile: Arnab Basu, Soroush Rais-Bahrami

Zitieren

APA

Basu, A., & Rais-Bahrami, S. (2024). Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae025

Vancouver

Basu A, Rais-Bahrami S. Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae025

BibTeX
@article{Basu2024,
  author = {Basu, Arnab and Rais-Bahrami, Soroush},
  title = {Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  doi = {10.1093/jnci/djae025}
}
Kostenlos starten →